Clene's COVID-19 Candidate Shows No Substantial Symptom Resolution In Phase 2 Trial

  • Clene Inc CLNN announced topline study results from its Phase 2 trial of CNM-ZnAg for non-hospitalized acutely symptomatic participants infected with COVID-19.
  • The Phase 2 trial assessed the efficacy and safety of CNM-ZnAg in COVID-19-infected participants in Brazil. Study participants were randomized to receive daily low-dose CNM-ZnAg, high-dose CNM-ZnAg, or placebo in addition to standard supportive care for up to 21 days. 
  • No clinical benefit was observed versus placebo. CNM-ZnAg was safe and well-tolerated, and no safety signals were identified.
  • Rob Etherington, Clene's CEO, commented, "While COVID has not been a therapeutic focus of the company, we were compelled to explore the potential of CNM-ZnAg to help address the global pandemic. At this time, we will cease further development for COVID."
  • CNM-ZnAg is an ionic solution of zinc and silver. CNM-ZnAg has broad-spectrum antiviral and antibacterial activity in multiple disease models.
  • In October, Clene's amyotrophic lateral sclerosis candidate, CNM-Au8, failed to show survival and functional benefit.
  • Price Action: CLNN shares closed 6.58% lower at $0.94 during after-hours trading on Tuesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!